Vaccine 1.0
From the public health perspective, vaccination is regarded as the most economical way of preserving healthy lives of people. Vaccines are regarded as public commodity and stockpiled in governmental institutions. Almost every nation has basal vaccina tion programs against common infectious diseases as an important health policy. Vac cines have very unique position in the pharmaceutical industries. Vaccines had used to represent less than 2% of the global pharmaceutical market. Since vaccines are com modity, pricing should be very reasonable that national budgets could afford stockpil ing and free vaccination to babies and citizens. In this regard, within pharmaceutical
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This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. and with the need of scale up production and the increase in the investment for large scale clinical trials, many local producers disappeared and were acquired by bigger companies. Eventually the vaccine industry became increasingly concentrated with a small num ber of major players. Until the end of the Vaccine 2.0 era, five major companies (GSK, Sanofi Aventis, Merck, Pfizer/Wyeth, and Novartis/Chiron) had over 80% of the global market. The biggest pressure to vaccine industry was safety concern and huge amount of investment for larger scale clinical trials to prove safety of vaccines. As vaccines become more widely used, many events of vaccine calamities accumulated, which resulted in keen public arousal concerning vaccine safety. Because of the public allergy to vaccination side effects, anti vaccination movements took power in developed countries [3] . With the aid of internet and other means of mass com munication, the antivaccination sentiment disseminated very rapidly. Consequently, the approval agencies became more cautious in approving new vaccines. The more the ap proval agencies become cautious, the more increased the costs for developing new vaccines. Naturally, the vaccine field remains at best a "qualified" market that is strongly regulated and has high entry barrier and supply constraints. Though competition among the major market players has been very keen, they competed within a field that was protected by a high entry barrier. Local producers and newly sprung high techbased small biotech companies were not allowed to the high barrierprotected global vaccine market.
K O R E A N V A C C I N E S O C I E T Y K O R E A N A C C I N E O C I E T Y V S
However, during the Vaccine 2.0 era, those major "monop sonistic" vaccine companies drastically changed the land scape of global vaccine industry. They globally expanded commercial vaccine markets over closed domestic and donor markets. Commercial markets are those markets, strongly regulated and intense competition exists and pricing is deter mined on the economical basis. Those big companies conse quently become more capable of investing big money in the research and development of more profitable premium vac cines. The premium vaccine market is by far the largest part in monetary value the global vaccine market [4] . After many years of neglect, big pharmaceutical companies rediscovered vaccines as a major growth opportunity. To expand the profit potential and competitive edge of their products, they began to actively adopt new breakthrough technologies. Now vaccine industry is no more thought to be "noneforprofit. " Among top 15 vaccines marketed in 2012, the number of commercial market vaccines exceeded noncommercial market vaccines (http://www.genengnews.com/insightandintelligence and153/top15vaccinesof2012/). Prevnar 13 and Gardasil were sold as much as 3.7 and 1.9 billion dollars, respectively. Vaccine 2.0 market is moving toward addressing chronic diseases, curing more adults, and using multivalent combina tion vaccines. However, conventional ways of vaccine devel opment governed the Vaccine 2.0 era seem to have almost reached to the limit. The global market landscape seems to be changing. Threats of emerging infections and bioterrorism changed public's attitude towards vaccine industry. Vaccine industry became an important component of national secu rity in developed countries. However, it is obvious that five major multinational vaccine companies' capacity is far be hind the global needs of essential vaccines. Many countries started to encourage and subsidize domestic vaccine indus try for their national security, which lead to explosive expan sion of the field. In Korea, five pharmaceutical companies in vested approximately 500 million dollars in constructing vac cine production facilities during last two or three years. In the United States, many young companies are moving forward to the global market with newly approved vaccines. Same trend is observed in China, Taiwan, and India 
Vaccine 3.0
Vaccine research and development are experiencing a re naissance of interest from the global scientific community. This would be the potent driving force pushing the Vaccine 3.0 forward. There are four major reasons for this: 1) the lack of efficacious treatment for many devastating infections; 2) the emergence of multidrug resistant bacteria; 3) the need for improving the safety of the more traditional licensed vac cines; and finally, 4) the great promise for innovative vaccine design and research with convergence of omics sciences, such as genomics, proteomics, immunomics, and vaccinolo gy [2] . The harbinger of Vaccine 3.0 should be the first ap proval of meningococcus type B vaccine developed by the re verse vaccinology techniques in 2011. This approach changed the direction of conventional vaccine development [2, 5] . The use of reverse vaccinology triggered a cascade of changes that affected the entire vaccine development process, shifting the focus from the identification of a list of vaccine candidates to the definition of a set of high throughput screens to reduce the need for costly and labor intensive tests in animal mod els. Rino Rappuoli, the father of reverse vaccinology, address es that a deep understanding of the epidemiology of vaccine candidates, and their regulation and role in hostpathogen interactions, must become an integral component of the screening workflow [5] . To cope with Vaccine 3.0 evolution, vaccinologist should develop new paradigm approaches for research and development. Following is the list of new appro aches that seem to contribute to the Vaccine 3.0 paradigm.
Systems biological analysis of microbial pathogenesis
Reverse vaccinology approaches exposed some adverse con cerns: they are genomic and antigenic variability among pathogens, needs for the indepth study of population genom ics and epidemiology of bacterial species, incomplete knowl edge about in vivo gene expression regulation, needs for im provements in bioinformatics algorithms and functional ge nomic analyses, etc. Generally single subunit vaccines are less efficacious than whole cell vaccines. For the establishment of successful infection, multiple virulence factors interact with host factors. Multifactorial systems biologic approach will pro vide more holistic understanding over molecular pathogene sis and make the discovery of new pathogenic mechanisms possible. This will fill the gaps in current reverse vaccinology.
Conquering immunosenescence and development of vaccination strategies for the elderly population
In industrialized countries, the strongest demographic driving force for the growth of vaccine field. The growth of vaccina tion in developed countries is largely driven by the "senior citizen" segment of the population that is continuously ex panding. Already, with vaccines directed at the prevention of influenza, pneumococcal infections, and zoster, in addition to the requirement of booster immunization, elderly vaccine has a huge growth potential [4] . However, the efficacy and ef fectiveness of vaccines exponentially decrease by aging. This becomes most apparent after a subject ages over 6570 years, and results from complex changes in the immune system [6] . In developed countries, average life expectancy exceeds 80 years and most elderly people are vulnerable to infectious disease that will impose a huge burden to the community. As such, it is urgently required to develop new vaccine formula tions and strategies that can overcome immunosenescence.
Search for safer and intelligent adjuvants
Both vaccine companies and approval authorities have been reluctant adopting new adjuvants to existing vaccines be cause of safety concerns. Immunopotentiating activities of vaccine adjuvants would increase the risk of reactogenicity. Until pathogen associated molecular pattern and pattern rec ognition receptor biology was elucidated, adjuvants were empirically incorporated to vaccines. Until couple of years ago, alum was the only vaccine adjuvant approved by Food and Drug Administration (FDA) and European Medicines Agency (EMEA). However, in the future, it is inevitable incor porating adjuvants in vaccines to enhance efficacy in elderly population and to save doses to immunize more people. Ad juvant can be used to induce desirable immune responses (humoral immunity or cell mediate immunity; Th1, or Th2, or Th17, or Treg) in the right immune compartment [7] . should be incorporated into existing vaccine formulations. For example, DNA vaccines, criticized to be ineffective in hu mans, are now under robust clinical trials in human subjects after new electroporation apparatuses were invented. New methods of administering vaccines are being actively devel oped, such as skin patches, aerosols via inhalation devices. Therapeutic vaccines will take larger share in the future vac cine market. Combinations of vaccines are becoming more common; mixing five to six or more components in a formu lation. Vaccines against noninfectious disease will also con tribute to the landscape of Vaccine 3.0. Anticancer immuno therapy and vaccines should be embraced by the vaccine in dustry. There are very active approaches to tackle metabolic syndromes with vaccine paradigm. These approaches cannot be successfully carried out by a single discipline. Stateofthe art disciplines of biology, immunology, medicine, chemistry, and engineering should very actively cooperate each other to make them successful. Vaccine community should be very open to diverse disciplines and new technologies and try to absorb them to nurture the Vaccine 3.0. In this regard, Kore an Vaccine Society and its official journal Clin Exp Vaccine Res, to contribute to the Vaccine 3.0 evolution, should be come the open platform where those diverse science disci plines and technologies could chemically interact.
Multidisciplinary convergence of new technologies and new concepts

